Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Tongzhou Hu"'
Publikováno v:
Current Pharmaceutical Biotechnology. 23:1772-1780
Background:Osteoarthritis is a type of age-related, chronic, and degenerative joint disease. Ezetimibe, a cholesterol absorption inhibitor, is widely used for the treatment of various diseases. However, the role of ezetimibe in osteoarthritis remains
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d769878dcbebfeeebcfa847e65afbb39
https://doi.org/10.2174/1389201023666220104141521
https://doi.org/10.2174/1389201023666220104141521
Publikováno v:
Letters in Drug Design & Discovery. 20
Introduction: Osteosarcoma is one of the most prevalent malignant bone tumors with a poor overall prognosis and mainly happens in children and adolescents. Current therapy strategies still possess a lot of limitations, and new and efficient strategie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3a4031d68163a603dd24d854d7c55af
https://doi.org/10.2174/1570180820666230418113909
https://doi.org/10.2174/1570180820666230418113909
Publikováno v:
Current computer-aided drug design.
Background: Rhizoma drynariae, a classic prescription in traditional Chinese medicine, has long been used for the treatment of osteonecrosis of the femoral head (ONFH), but its potential targets and molecular mechanisms remain to be further explored.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::638162ffa7e7df2dc7e6b9de748aa0a3
https://pubmed.ncbi.nlm.nih.gov/36201277
https://pubmed.ncbi.nlm.nih.gov/36201277
Publikováno v:
Toxicology and Applied Pharmacology. 371:55-62
Background Development of doxorubicin-resistance is the main difficulty for osteosarcoma treatment. LncRNA Taurine upregulated gene 1 (TUG1) has been identified as oncogenic lncRNA in different types of carcinomas and was involved in chemoresistance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4936f2c53ec5750fa9d1196b42855870
https://doi.org/10.1016/j.taap.2019.04.005
https://doi.org/10.1016/j.taap.2019.04.005
Publikováno v:
Current pharmaceutical biotechnology. 23(14)
Osteoarthritis is a type of age-related, chronic, and degenerative joint disease. Ezetimibe, a cholesterol absorption inhibitor, is widely used for the treatment of various diseases. However, the role of ezetimibe in osteoarthritis remains unclear.Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a99382fe80fdcf74f42965c82ad6ebef
https://pubmed.ncbi.nlm.nih.gov/34983342
https://pubmed.ncbi.nlm.nih.gov/34983342
Publikováno v:
Journal of drug targeting. 28(2)
Development of cisplatin (DDP)-resistance is a major challenge that largely limits the efficacy of chemotherapy for osteosarcoma. LncRNA Taurine up-regulated gene 1 (TUG1) is a recently identified oncogenic lncRNA that has been involved in chemo-resi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ce92e0f8d7eccd56b96d27143d813d3
https://pubmed.ncbi.nlm.nih.gov/31305159
https://pubmed.ncbi.nlm.nih.gov/31305159
Publikováno v:
Pharmacological reports : PR. 69(6)
The response of conventional chemotherapy for osteosarcoma treatment is usually poor, and chemotherapy-related severe side effects and drug resistance remain a problem. Abundant evidence has shown that Astragaloside IV, extracted from Astragalus memb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b809513b6d43661dcbc237cbfb6b86f
https://pubmed.ncbi.nlm.nih.gov/29128795
https://pubmed.ncbi.nlm.nih.gov/29128795
Autor:
Li Zhang, Tongzhou Huang, Jianing Bi, Yingying Zheng, Chao Lu, Qi Hui, Xiaojie Wang, Xiaohua Lin
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
We developed a highly stable recombinant human acidic fibroblast growth factor (rh-aFGF) carbomer 940 hydrogel for wound healing. This study aimed to reveal toxicity target organs and the toxicity dose-response in the long-term administration of rh-a
Externí odkaz:
https://doaj.org/article/f4f4d5bafd7e4fa2a23fa620fbe94bc3
Autor:
Jiawei Huang, Mengyuan Qiu, Li Wan, Gui Wang, Tongzhou Huang, Zhixin Chen, Songmin Jiang, Xiaokun Li, Lixiao Xie, Lin Cai
Publikováno v:
Cellular Physiology and Biochemistry, Vol 45, Iss 4, Pp 1690-1699 (2018)
Background/Aims: TGF-β1 is beneficial during early liver disease but is tumor-progressive during late stages especially for hepatocellular carcinoma (HCC). Thus, exploring the underlying mechanisms may provide information about a potentially therape
Externí odkaz:
https://doaj.org/article/d356ae873d0d4087b064438daa130f72